MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED (MVP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MVP - MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences

Year End: June

GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences

Debt/EBITDA: -0.17

Index:

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$0.61 29 Apr 2025	0.145 OPEN $0.51	31.18% HIGH $0.74	1,485,471 LOW $0.51

TARGET

$0.80

+0.09 change from previous day

31.1% upside

Franking for last dividend paid out: 100%

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .

FNARENA'S MARKET CONSENSUS FORECASTS

Title	FY23 Actual	FY24 Actual	FY25 Forecast	FY26 Forecast
EPS (cps)	xxx	- 46.3	- 0.0	xxx
DPS (cps)	xxx	0.0	0.0	xxx
EPS Growth	xxx	N/A	N/A	xxx
DPS Growth	xxx	N/A	N/A	xxx
PE Ratio	xxx	N/A	N/A	xxx
Dividend Yield	xxx	N/A	0.0%	xxx
Div Pay Ratio(%)	xxx	N/A	N/A	xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 05/03 - ex-div 2c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2025 FactSet UK Limited. All rights reserved

Title	2019	2020	2021	2022	2023	2024
EPS Basic	xxx	xxx	xxx	xxx	xxx	-46.3
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	33.1 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	51.6
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	-10.8 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	-123.66 %

EPS Basic

Negative
Growth
Slowing

DPS All

Negative
Growth
Slowing

Sales/Revenue

Negative
Growth
Slowing

Book Value Per Share

Negative
Growth
Slowing

Net Operating Cash Flow

Negative
Growth
Slowing

Net Profit Margin

Negative
Growth
Slowing

Title	2019	2020	2021	2022	2023	2024
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-64.53 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-62.50 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	-47.32 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-64.53 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-25.58 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	-11.6 M

Return on Capital Employed

Negative
Growth
Slowing

Return on Invested Capital

Negative
Growth
Slowing

Return on Assets

Negative
Growth
Slowing

Return on Equity

Negative
Growth
Slowing

Return on Total Capital

Negative
Growth
Slowing

Free Cash Flow ex dividends

Negative
Growth
Slowing

Title	2019	2020	2021	2022	2023	2024
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	0 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	2 M
Total Debt	xxx	xxx	xxx	xxx	xxx	2 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	9 M
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	10 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	0.76

Short-Term Debt

Negative
Growth
Slowing

Long Term Debt

Negative
Growth
Slowing

Total Debt

Negative
Growth
Slowing

Goodwill - Gross

Negative
Growth
Slowing

Cash & Equivalents - Generic

Negative
Growth
Slowing

Price To Book Value

Negative
Growth
Slowing

Title	2019	2020	2021	2022	2023	2024
Capex	xxx	xxx	xxx	xxx	xxx	3.2 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	9.56 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	36 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	14 M
Research & Development	xxx	xxx	xxx	xxx	xxx	-
Investments - Total	xxx	xxx	xxx	xxx	xxx	0 M

Capex

Negative
Growth
Slowing

Capex % of Sales

Negative
Growth
Slowing

Cost of Goods Sold

Negative
Growth
Slowing

Selling, General & Admin. Exp & Other

Negative
Growth
Slowing

Research & Development

Negative
Growth
Slowing

Investments - Total

Negative
Growth
Slowing

Negative

Growth

Slowing

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Bell Potter	30/04/2025	1	Upgrade to Speculative Buy from Hold	$0.80	31.15%	Bell Potter raises its target for Medical Developments International to 80c from 71c, driven by a lower discount rate and adjusted valuation weighting, and upgrades to Speculative Buy from Hold Management delivered a surprise positive operating cash flow of approximately $1.7m in the March quarter, observe the analysts. This represents a $5.6m improvement year-on-year, and turns year-to-date cash flow to a positive $0.9m, up $11m from the prior year. Cash flows benefited from favourable debtor payment timing, but Bell Potter cautions the June quarter may show negative cash flow as working capital shifts and inventory is built for the US respiratory season. A new distribution agreement has been signed with Ethypharm to accelerate Penthrox sales in France, leveraging Ethypharm’s established position in pain and addiction therapies across Europe, explains Bell Potter. FORECAST Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.01 cents. Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.02 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Bell Potter

30/04/2025

Upgrade to Speculative Buy from Hold

$0.80

31.15%

Bell Potter raises its target for Medical Developments International to 80c from 71c, driven by a lower discount rate and adjusted valuation weighting, and upgrades to Speculative Buy from Hold

Management delivered a surprise positive operating cash flow of approximately $1.7m in the March quarter, observe the analysts. This represents a $5.6m improvement year-on-year, and turns year-to-date cash flow to a positive $0.9m, up $11m from the prior year.

Cash flows benefited from favourable debtor payment timing, but Bell Potter cautions the June quarter may show negative cash flow as working capital shifts and inventory is built for the US respiratory season.

A new distribution agreement has been signed with Ethypharm to accelerate Penthrox sales in France, leveraging Ethypharm’s established position in pain and addiction therapies across Europe, explains Bell Potter.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.01 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.02 cents.

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
No data available in table

Access Extra Coverage Research History >

MVP STOCK CHART

FNArena News on MVP

1	Weekly Ratings, Targets, Forecast Changes – 28-03-25 Mar 31 2025 - Weekly Reports

2	FNArena Corporate Results Monitor – 01-09-2023 Sep 01 2023 - Australia

3	Australian Broker Call Extra Edition – Mar 08, 2023 Mar 08 2023 - Daily Market Reports

4	Australian Broker Call Extra Edition – Nov 01, 2022 Nov 01 2022 - Daily Market Reports

5	Australian Broker Call Extra Edition – Oct 11, 2022 Oct 11 2022 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1	Behring Margin Outlook Still Main Game For CSL Feb 13 2025 - Australia

2	Dr Boreham’s Crucible: Arovella Therapeutics Aug 29 2024 - Small Caps

3	ResMed’s Margin Upside Excites Aug 07 2024 - Australia

4	Dr Boreham’s Crucible: Aroa Biosurgery Jul 29 2024 - Small Caps

5	CSL Shares Breaking Free Jul 23 2024 - Technicals

6	Dr Boreham’s Crucible: SDI Jul 19 2024 - Small Caps

7	‘Defensive’ Pharmaceutical Wholesalers In Focus Jul 18 2024 - Australia

8	Twists And Turns Of Telix And Australian Biotech Jul 10 2024 - Small Caps

9	Dr Boreham’s Crucible: Radiopharm Theranostics Jul 03 2024 - Small Caps

10	Dr Boreham’s Crucible: Island Therapeutics Jun 17 2024 - Small Caps

Dividend Yield Today On Last Actual Payout :	0.00
Estimated Dividend Growth (Average Of Past Three Years)	%
Amount Invested	$
Tell Me The Dividend After This Many Years

	Yield	Yield on investment
This Year
Year 1
Year 2
Year 3
Year 4
Year

1	Weekly Ratings, Targets, Forecast Changes – 28-03-25 Mar 31 2025 - Weekly Reports

2	FNArena Corporate Results Monitor – 01-09-2023 Sep 01 2023 - Australia

3	Australian Broker Call Extra Edition – Mar 08, 2023 Mar 08 2023 - Daily Market Reports

4	Australian Broker Call Extra Edition – Nov 01, 2022 Nov 01 2022 - Daily Market Reports

5	Australian Broker Call Extra Edition – Oct 11, 2022 Oct 11 2022 - Daily Market Reports

Get 2 Weeks free trial

Sign Up

Member Login

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED (MVP)
Share Price Analysis and Chart